Protagonist Therapeutics, Inc - Common Stock (PTGX)
CUSIP: 74366E102
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 62,457,444
- Total 13F shares
- 56,731,936
- Share change
- +3,573,160
- Total reported value
- $1,566,841,397
- Put/Call ratio
- 41%
- Price per share
- $27.62
- Number of holders
- 163
- Value change
- +$104,873,016
- Number of buys
- 101
- Number of sells
- 60
Quarterly Holders Quick Answers
What is CUSIP 74366E102?
CUSIP 74366E102 identifies PTGX - Protagonist Therapeutics, Inc - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74366E102:
Top shareholders of PTGX - Protagonist Therapeutics, Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
13F
|
Company |
7.4%
|
4,600,799
|
$105,818,377 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
7%
|
4,402,217
|
$101,250,991 | — | 31 Mar 2023 | |
| BVF INC/IL |
13F
|
Company |
6%
|
3,775,900
|
$86,845,700 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.2%
|
3,241,293
|
$74,549,739 | — | 31 Mar 2023 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.2%
|
2,615,014
|
$60,145,322 | — | 31 Mar 2023 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
4.1%
|
2,558,000
|
$58,834,000 | — | 31 Mar 2023 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.9%
|
2,449,183
|
$56,331,209 | — | 31 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
3.9%
|
2,413,701
|
$55,514,803 | — | 31 Mar 2023 | |
| Cormorant Asset Management, LP |
13F
|
Company |
2.7%
|
1,700,000
|
$39,100,000 | — | 31 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
2.5%
|
1,570,510
|
$36,121,730 | — | 31 Mar 2023 | |
| Kynam Capital Management, LP |
13F
|
Company |
2.2%
|
1,375,000
|
$31,625,000 | — | 31 Mar 2023 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.2%
|
1,366,080
|
$31,419,840 | — | 31 Mar 2023 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2%
|
1,262,259
|
$29,031,181 | — | 31 Mar 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.9%
|
1,164,680
|
$26,787,640 | — | 31 Mar 2023 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.8%
|
1,122,342
|
$25,814,000 | — | 31 Mar 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.5%
|
965,152
|
$22,198,496 | — | 31 Mar 2023 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.5%
|
958,891
|
$22,054,493 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
925,993
|
$21,297,847 | — | 31 Mar 2023 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
1.3%
|
828,471
|
$19,055,000 | — | 31 Mar 2023 | |
| 683 Capital Management, LLC |
13F
|
Company |
1.3%
|
791,000
|
$18,193,000 | — | 31 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.2%
|
766,990
|
$17,640,770 | — | 31 Mar 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.1%
|
690,867
|
$15,890,000 | — | 31 Mar 2023 | |
| Woodline Partners LP |
13F
|
Company |
0.99%
|
618,615
|
$14,228,145 | — | 31 Mar 2023 | |
| BARCLAYS PLC |
13F
|
Company |
0.93%
|
583,737
|
$13,425,951 | — | 31 Mar 2023 | |
| S.c.a. Candriam |
13F
|
Individual |
1%
|
625,000
|
$13,231,166 | — | 31 Mar 2023 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.75%
|
465,323
|
$10,702,429 | — | 31 Mar 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.74%
|
459,450
|
$10,567,350 | — | 31 Mar 2023 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.72%
|
449,800
|
$10,345,400 | — | 31 Mar 2023 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.69%
|
428,938
|
$9,865,574 | — | 31 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.68%
|
422,636
|
$9,720,628 | — | 31 Mar 2023 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.66%
|
415,274
|
$9,552,000 | — | 31 Mar 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.58%
|
361,158
|
$8,306,634 | — | 31 Mar 2023 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.53%
|
331,282
|
$7,619,486 | — | 31 Mar 2023 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.49%
|
307,700
|
$7,077,100 | — | 31 Mar 2023 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.48%
|
301,000
|
$6,923,000 | — | 31 Mar 2023 | |
| Invesco Ltd. |
13F
|
Company |
0.45%
|
277,936
|
$6,392,528 | — | 31 Mar 2023 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.38%
|
237,624
|
$5,465,352 | — | 31 Mar 2023 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.36%
|
225,000
|
$5,175,000 | — | 31 Mar 2023 | |
| Allspring Global Investments Holdings, LLC |
13F
|
Company |
0.36%
|
223,664
|
$5,144,272 | — | 31 Mar 2023 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.35%
|
220,991
|
$5,082,793 | — | 31 Mar 2023 | |
| Gratus Capital, LLC |
13F
|
Company |
0.34%
|
211,731
|
$4,869,813 | — | 31 Mar 2023 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.32%
|
199,516
|
$4,588,868 | — | 31 Mar 2023 | |
| CITIGROUP INC |
13F
|
Company |
0.31%
|
192,349
|
$4,424,027 | — | 31 Mar 2023 | |
| David Y. Liu |
3/4/5
|
Chief R&D Strategy Officer |
—
class O/S missing
|
167,590
|
$4,127,742 | — | 16 Nov 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.27%
|
168,533
|
$3,876,259 | — | 31 Mar 2023 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.25%
|
153,387
|
$3,527,901 | — | 31 Mar 2023 | |
| GREAT LAKES ADVISORS, LLC |
13F
|
Company |
0.24%
|
150,484
|
$3,461,130 | — | 31 Mar 2023 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.24%
|
148,992
|
$3,426,816 | — | 31 Mar 2023 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.23%
|
146,000
|
$3,358,000 | — | 31 Mar 2023 | |
| Tri Locum Partners LP |
13F
|
Company |
0.21%
|
133,452
|
$3,069,396 | — | 31 Mar 2023 |
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q2 2023
As of 30 Jun 2023,
Protagonist Therapeutics, Inc - Common Stock (PTGX) was held by
163 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,731,936 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, BVF INC/IL, STATE STREET CORP, VANGUARD GROUP INC, JOHNSON & JOHNSON, COWEN AND COMPANY, LLC, Cormorant Asset Management, LP, and PERCEPTIVE ADVISORS LLC.
This page lists
164
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
135
Q2 2023 holders
163
Holder diff
28
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.